Signos, a San Francisco, CA-based metabolic health platform that utilizes AI and continuous glucose monitoring (CGM), raised $20 million in Series B funding.
The round was led by Cheyenne Ventures and GV (Google Ventures), with additional investments from Dexcom Ventures and Samsung.
Cheyenne Ventures is a venture capital firm dedicated to investing in life-changing companies that redefine a new generation of technology, consumer products, and healthcare.
GV (Google Ventures) is a venture capital investment arm of Alphabet Inc. GV provides seed, venture, and growth-stage funding to technology companies. They invest across the life sciences, consumer, enterprise, crypto, climate, and frontier technology sectors.
Signos Use of Funds
The funds will be used to expand the team, extend the platform's capabilities, and conduct further research on metabolic health.
Founded in 2018, Signos is a comprehensive metabolic health platform that includes a proprietary AI engine with a continuous glucose monitor (CGM) to provide real-time data and recommendations for healthy weight management. Signos offers an app that allows users to track their food intake and exercise levels. The AI platform learns how an individual's metabolism responds to different foods and fitness patterns, providing personalized recommendations based on the user's unique metabolic profile.
Company: Signos, Inc.
Round: Series B
Funding Month: October 2023
Lead Investors: Cheyenne Ventures and GV (Google Ventures)
Additional Investors: Dexcom Ventures and Samsung
Company Website: https://www.signos.com/
Software Category: Metabolic Health Platform